The growing competition between Novo Nordisk and Eli Lilly in diabetes and obesity has been one of the biggest stories of 2023, and venture capital firm Forbion has been a major beneficiary, selling a cardiometabolic biotech company to each of the rivals this year.
Fueled By Lilly And Novo Buy-Outs, Forbion Looks To Make Most Of ‘Buyers’ Market’
Forbion’s Sander Slootweg looks back over the company’s most successful year so far, and looks ahead at likely market and therapy area trends for 2024.
